Welcome to the Abel Lab
Care Delivery Research for Patients with Blood Cancers
The Abel Lab at Dana-Farber Cancer Institute applies health services research methods to understand the experiences of patients with blood cancers and develop interventions to improve care.
|
We are interested in evaluating how cancer and its therapies affect outcomes such as function and quality of life. Through our work and collaboration with researchers in oncology, hematology, geriatrics, ethics, and energy balance, we aim to ameliorate the impact of hematologic malignancies and their treatment from diagnosis to the end of life. |
|
|
|
Dr. Hantel describes results of an Abel Lab national survey presented at the 2023 annual meeting of the American Society of Hematology. We assessed the perceptions of oncology clinicians about the ethics and impact of artificial intelligence for the care of patients with cancer. Explore this website to learn about our current research and former projects. |
Lab News — September 2024 |
- We welcome Dr. Eric Blackstone, a new post-doctoral bioethics fellow, to the Abel Lab.
- “Cancer trial eligibility and therapy modifications for individuals with Duffy Null–associated neutrophil count,” featuring several authors from the Abel lab, was published in JAMA Network Open.
- Dr. Korenteng’s analysis “Clinical ethics consultation services: public-facing information on NCI-designated cancer center websites” was published in The Oncologist.
- Dr. Hantel’s analysis “A focus group study of ethical issues during climate-informed health decision-making” was published in Nature Climate Change.
|
|
|